research use only
Cat.No.S9818
| Related Targets | CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras KRas |
|---|---|
| Other FPR Inhibitors | HCH6-1 N-Formyl-Met-Leu-Phe (fMLP) FPR Agonist 43 BMS-986235 |
|
In vitro |
DMSO
: 100 mg/mL
(90.55 mM)
Water : 50 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 1104.27 | Formula | C61H65N15O6 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 878557-55-2 | -- | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
FPRL1
(Cell-free assay) 0.23 μM
|
|---|---|
| In vitro |
WRW4 shows potent activity in terms of inhibiting WKYMVm binding to FPRL1. It inhibits the activation of FPRL1 by WKYMVm, resulting in the complete inhibition of the intracellular calcium increase, extracellular signal-regulated kinase activation, and chemotactic migration of cells toward WKYMVm. This compound specifically inhibits the increase in intracellular calcium by the FPRL1 agonists MMK-1, amyloid β42 (Aβ42) peptide, and F peptide, but not by the FPR agonist, fMLF. Aβ42 peptide-induced superoxide generation and chemotactic migration of neutrophils are inhibited by this chemical, which also completely inhibits the internalization of Aβ42 peptide in human macrophages. |
| In vivo |
Male Swiss mice undergo intraplantar (i.pl.) injection with complete Freund’s adjuvant (CFA). WRW4 prevents the antihyperalgesic effect induced by either EA or BML-111. EA increases ANXA1 but does not alter FPR2/ALX receptor levels in the paw. Furthermore, i.pl. pretreatment with this compound prevents the increase of ANXA1 levels induced by EA. |
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.